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Abstract
Background: We aimed to determine the degree to which control targets of glycaemia and cardiovascular risk
factors were achieved among patients with type 2 diabetes and to investigate sex- and age-related differences in
this population.
Methods: This cross-sectional, population-based study was conducted in Spain. Glycated hemoglobin (HbA1c),
blood pressure, LDL-c, HDL-c, triglycerides, BMI, and smoking history were obtained from electronic clinical primary
care records (n = 32,638 cases). The proportions of patients who met control targets were determined according to
sex and age groups. Comparisons between groups were conducted with t-tests for continuous variables, tests for
trends in proportions for categorical and ordinal variables, and Pearson’s chi-square tests and binary logistic
regression models for categorical variables.
Results: The overall proportions of patients with type 2 diabetes who met the target objectives for HbA1c (<7 %,
53 mmol/mol), blood pressure (130/80 mmHg), and LDL-cholesterol (100 mg/dl) were 60, 40 and 41 %, respectively.
Women were less likely than men to meet the control targets of HbA1c (59 vs 61 %), LDL (35 vs 45 %), and HDL
(58 vs 78 %). Patients under 65 years of age presented poorer control than older age groups. Only a minority of
patients with type 2 diabetes met the composite target objectives for glycemic control, blood pressure, and LDL.
Conclusions: There are differential gaps in the control results of female patients and younger patients, which
should prompt improvements in case management and care. There is room for further improvement in the
cardiometabolic control of patients with type 2 diabetes.
Keywords: Type 2 diabetes, Control targets, Health inequalities, Glycemic control, Cardiovascular risk factors
Background
In 2015, there were an estimated 415 million diabetics
worldwide, corresponding to 8.3 % of the population.
This figure is estimated to increase to 642 million by
2040 [1]. The di@betes study in Spain found that 13.8 %
of the population over 18 years of age had type 2
diabetes, and almost half of those cases (6 %) were
undiagnosed [2].
Chronic complications of diabetes impose morbidities
that reduce life quality and expectancy. The Diabetes
Control and Complication Trial (DCCT) and the United
Kingdom Prospective Diabetes Study (UKPDS) showed
that improved glycemic control was associated with a
reduction in the risk of complications in type 1 and type
2 diabetics, respectively, and subsequent studies have
shown that patients with diabetes can largely reduce the
risk of cardiovascular disease by lowering blood pressure
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and LDL-cholesterol levels and avoiding tobacco con-
sumption [3–8]. Accordingly, there has been a broad
consensus in recent years to develop and extensively im-
plement clinical practice guidelines for diabetes care and
treatment [9–12].
However, despite the scientific evidence and the high
degree of consensus reached by experts, clinicians, and
planners, achieving control targets remains a challenge.
Several studies have shown that there is an important gap
between recommendations and clinical practice, and only
a minority of diabetic patients achieve the optimal control
of glycaemia and cardiovascular risk factors [13–18].
Electronic information systems that maintain updated
information on every contact with patients are promis-
ing sources of information, particularly for the identifica-
tion of health needs and the evaluation of interventions,
because they can provide clinical practice information in
real conditions. Thus, electronic information systems
may help characterize which diabetic patients achieve or
do not achieve control targets and may help identify the
factors that determine those achievements, both of
which are key issues to optimize in intervention
strategies.
This population-based study used existing electronic
medical primary care records. The aims of this study
were to assess the actual degree of achievement of gly-
cemic control and cardiovascular risk factors and to
investigate differences by sex and age among patients
with type 2 diabetes.
Methods
This cross-sectional study was conducted in Navarra, a
community in northern Spain with over 600,000 inhabi-
tants. In Navarra, Primary Care was developed in the
1980s and provides universal health coverage to the
population. The territory is divided into 57 Basic Zones,
each of which contains a team of general practitioners,
nurses, and pediatricians who belong to the Regional
Health Service of Navarre (RHSN). The populations
of the Basic Zones range from 5000 inhabitants in
rural areas to 25,000 in urban areas. The RHSN is
essentially financed by general taxes, and health
services, hospitalizations, and diagnostic procedures
are free of charge for all citizens. A fraction of the
medication cost is paid by patients, depending on
their work status and income. Antidiabetic drugs are
subsidized at least by 90 %.
Within the RHSN, all patients with type 2 diabetes are
managed by primary care teams. If the patients do not
achieve an acceptable glycemic control they are derived
to the ambulatory specialized care and then attended by
endocrinologists. Also, they are treated by specialists
when they are hospitalized or have complications. Thus,
the Primary Care Electronic Medical Record System,
named Atenea, contains information related to all the
patients with type 2 diabetes managed by the RHSN.
Specifically, it contains data about diagnoses, clinical
variables, life styles, laboratory results, and prescriptions.
Primary care electronic medical records were established
in Navarra in the early 2000s and have been thoroughly
used by all professionals since 2008. Electronic prescrip-
tions were established in 2013.
Study population and selection of study variables
The study population comprised all of the patients who
were registered in Atenea with a diagnosis of type 2 dia-
betes (International Classification of Primary Care (ICPC),
T90) on May 15th, 2014. We obtained the following pa-
tient information: glycated hemoglobin (HbA1c), systolic
and diastolic blood pressure (SBP and DBP), LDL- and
HDL- cholesterol levels, triglycerides, weight, height, body
mass index (BMI), smoking history, medications, date of
registration in the information system, date of diabetic on-
set, and birth date. We obtained the latest results available
within the 15 months prior to the data extraction date.
We provide the number of data entries available for each
of the study variables. Missing values imply that the pa-
tients had not had controls performed within the previous
15 months, and they can be regarded as a negative indica-
tor of the process of care.
Statistical analysis
The continuous variables were summarized by the mean
and standard deviation; the categorical variables were sum-
marized by frequencies. Comparisons by gender and age
groups were conducted with t-tests for continuous vari-
ables, tests for trends in proportions for ordinal variables,
and Pearson’s chi-square tests for categorical variables. The
differences in the degree of achievement of control targets
between men and women were assessed by binary logistic
regression models, which included age and the duration of
diabetes as covariates. The statistical analyses were con-
ducted with IMB-SPSS 20 and R 3.2.0.
Results
The total number of registered Navarra Regional Health
Service patients over 20 years of age with type 2 diabetes
was 32,638. There were 18,188 men and 14,018 women
with diabetes, which yielded an overall prevalence of 6.6 %
(95 % CI: 6.5, 6.7 %) or 7.5 % (95 % CI: 7.4, 7.6 %) in males
and 5.6 % (95 % CI: 5.5, 5.7 %) in females. The prevalence
of diabetes was higher in men than in women among all
age groups, peaking in the 80–85 year old group (25 %)
and in the 85–90 year old group (20 %) for men and
women, respectively (Additional file 1: Table S1).
Data availability and the characteristics of the patients
are summarized in Table 1. There were strong differ-
ences in the number of missing values among the study
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variables. Virtually all of the patients had age properly
recorded, and sex was missing in only 432 (1.3 %) cases.
Approximately 75 % of the patients had laboratory
results and blood pressure (BP) records. However, BMI,
the duration of diabetes, and smoking history were
poorly recorded with missing values in 47, 55, and 62 %
of the patients, respectively. Cardiometabolic controls
were less frequently performed in male and female pa-
tients younger than 65 years of age than in older groups.
In fact, the proportion of patients with valid data was
approximately 10 percentage points lower in this age
group than in patients between 65 and 74 years old
(Additional file 2: Table S2).
The mean age of the patients with type 2 diabetes was
69.5 years, and women were older (72.4 years) than men
(67.3 years) (p <0.001). The overall duration of diabetes
was 10.2 years, and the duration was an average of 1 year
longer among women (Table 1).
The average HbA1c level was 7.1 % (64 mmol/mol),
both in men and in women; 60.1 % of the patients had
HbA1c levels less than 7 % (53 mmol/mol), 82.9 % had
HbA1c levels less than 8 % (64 mmol/mol), and 3.4 %
had HbA1c levels greater than 10 % (86 mmol/mol)
(Tables 1 and 2). The proportion of patients with HbA1c
levels less than 7 % (53 mmol/mol) was higher among
males (61.2 %) than among females (58.8 %) (p <0.001).
Adjusting for age, the odds of having HbA1c levels
greater than 7 % were 12 % higher among women than
among men (OR 1.12, 95 % CI: 1.06–1.19). Similar esti-
mates were obtained after adjusting for age and diabetes
duration (OR 1.13, 95 % CI: 1.04–1.24). Some differ-
ences between age groups were observed. Among men,
the proportion of patients with HbA1c levels less than
7 % (53 mmol/mol) was lower in the group younger than
65 years, whereas among women, there was no signifi-
cant difference between age groups (p = 0.958) (Fig. 1).
In both sexes, the group younger than 65 years of age
had the highest proportion of patients with an HbA1c
level greater than 10 % (86 mmol/mol); this proportion
was double the prevalence of all other age groups.
On average, women had slightly lower diastolic BP
than men (Table 1), but the control targets were
achieved essentially in the same proportions of men and
women; 69.9 % of the patients had a BP less than 140/
Table 1 Data availability, characteristics and clinical parameters of the population of patients with diagnosed diabetes by sex.
Navarra (Spain), 2014
Data available Total Men Women
Variable n (%) n (%) n (%) n (%) p
Sex 32,206 (98.7) 18,188 (57.47) 14,018 (43.2)
Age group 32,638 (100)
<65 years 10,803 (33.1) 7138 (39.2) 3475 (24.8)
65–74 years 9377 (28.7) 5618 (30.9) 3678 (26.2) <0.001
≥75 years 12,458 (38.2) 5432 (29.9) 6865 (49.0)
Treatment 32,638 (100)
Insulin 6639 (20.3) 3432 (18.9) 3161 (22.5) <0.001
Oral hypoglycemic 18,551 (56.8) 10,731 (59.0) 7684 (54.8)
No medication 7448 (22.8) 4025 (22.1) 3173 (22.6)
Smoking 12,413 (38) 1190 (16.0) 1519 (21.3) 459 (8.8) <0.001
Mean (SD) Mean (SD) Mean (SD)
Age (yrs) 32,638 (100) 69.49 (12.82) 67.31 (12.17) 72.4 (13.02) <0.001
Diabetes duration (yrs) 14,472 (44.3) 10.21 (7.26) 9.81 (7.11) 10.78 (7.45) <0.001
HbA1c (%) 23,094 (70.8) 7.10 (2.94) 7.07 (3.59) 7.12 (1.83) 0.357
<65 years 7.16 (1.51) 7.16 (1.52) 7.16 (1.52) 0.998
65–74 years 7.02 (2.49) 6.95 (2.89) 7.12 (1.71) 0.006
≥75 years 7.11 (3.94) 7.13 (5.48) 7.10 (2.02) 0.700
Systolic BP (mmHg) 24,616 (75.4) 134.7 (17.3) 134.7 (16.8) 135.0 (17.9) 0.253
Diastolic BP (mmHg) 24,595 (75.4) 75.5 (10.51) 75.87 (10.50) 75.05 (10.45) <0.001
TGs (mg/dl) 24,381 (74.7) 146.9 (98.4) 146.0 (109.9) 148.1 (81.38) 0.088
HDL (mg/dl) 24,331 (74.5) 45.44 (12.47) 43.35 (11.82) 48.13 (12.74) <0.001
LDL (mg/dl) 23,891 (73.2) 109.1 (33.8) 106.2 (32.5) 113.8 (34.83) <0.001
BMI (mg/dl) 17,306 (53.0) 30.47 (9.12) 30.12 (7.95) 30.92 (10.44) <0.001
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90 mmHg, and 39.6 % had a BP less than 130/80 mmHg
(Table 2). No differences between sexes were observed
after adjusting for age and diabetes duration.
Overall, 40.5 % of the patients with diabetes had an
LDL level less than 100 mg/dl, 69.4 % had an HDL level
greater than the target level (35 mg/dl for men, 45 mg/
dl for women), and 64.5 % had fasting triglyceride levels
less than 150 mg/dl (Table 2). The mean LDL level was
109.1 mg/dl, and it was 7.6 mg/dl higher among women
than among men. Men were more likely to meet the
LDL control target than women among all age groups,
with differences up to 12 percentage points. Adjusting
for age, the odds of having an LDL greater than 100 mg/
dl was 60 % higher among women than among men (OR
1.60, 95 % CI: 1.52–1.69). Similar estimates were
obtained after adjusting for age and diabetes duration
(OR 1.58, 95 % CI: 1.46–1.72). Among both males and
females, patients under 65 years of age had the poorest
Table 2 Proportions (%) of patients with type 2 diabetes achieving control goals by sex and age group. Navarra (Spain), 2014
Men by age group (years) Women by age group (years)
Target Total All <65 65–74 ≥75 p All <65 65–74 ≥75 p
HbA1c ≤7 % (≤53 mmol/mol) 60.1 61.2 58.4 64.4 61.0 0.006 58.8 58.9 58.6 58.8 0.958
HbA1c ≤8 % (≤64 mmol/mol) 82.9 83.5 79.3 86.5 85.1 <0.001 82.2 80.3 83.1 82.5 0.048
HbA1c >10 % (>86 mmol/mol) 3.4 3.4 5.0 2.4 2.5 <0.001 3.5 5.7 2.8 2.8 <0.001
BP ≤130/80 mmHg 39.6 39.5 38.2 37.6 42.6 <0.001 39.6 44.9 39.4 37.6 <0.001
BP ≤140/90 mmHg 69.9 70.0 71.2 69.2 69.8 0.142 69.7 78.1 69.9 66.2 <0.001
LDL ≤100 mg/dl 40.5 44.7 38.6 46.1 49.9 <0.001 35.2 28.9 35.5 37.9 <0.001
HDL (≥35 M, ≥45 W)a 69.4 78.3 75.9 80.8 78.2 0.004 58.1 55.9 60.4 57.8 0.365
TGs <150 mg/dl 64.5 66.5 56.1 67.9 76.6 <0.001 62.2 57.9 61.3 64.6 <0.001
BMI <30 kg/m2 52.6 54.5 45.3 55.0 63.3 <0.001 50.3 39.2 44.1 59.4 <0.001
Not smoking 84.0 70.4 66.4 80.3 90.3 <0.001 91.2 74.6 92.1 97.8 <0.001
Combined targets:
Ab 13.8 16.1 13.0 17.7 17.9 <0.001 11.0 10.2 11.3 11.2 0.236
B c 16.3 18.4 13.0 17.7 25.4 <0.001 13.8 10.2 11.3 16.8 <0.001
aTarget: ≥35 mg/dL in men, and ≥45 mg/dl in women
bA: HbA1c <7 % (53 mmol/mol) & BP <140/90 mmHg & LDL <100 mg/dl
cB: HbA1c <7 % (<53 mmol/mol) if <75 years OR HbA1c <8 % (<64 mmol/mol) if ≥75 years & BP <140/90 mmHg & LDL <100 mg/dl
Fig. 1 By sex and age group, percentage of patients achieving glycemic and cardiovascular prevention goals. Navarre (Spain), 2014
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LDL control results (p <0.001). Regarding HDL, 78 % of
males and 58 % of females met the gender-specific
targets. Adjusting for age, the men’s odds of having HDL
levels greater than 35 mg/dL were 2.65 times higher
than the women’s odds of having HDL levels greater
than 45 mg/dL (OR 2.65, 95 % CI: 2.50–2.80).
The proportion of patients achieving the composite
triple target (simultaneous HbA1c <7 % (53 mmol/mol),
BP <140/90 mmHg, and LDL <100 mg/dl; target A in
Table 2) dramatically decreased to 14 % (16 % among
men and 11 % among women). Among men, the poorest
results were achieved in the group younger than 65 years
of age (p <0.001), whereas among women, no trend was
observed across age groups. Using less stringent targets
for HbA1c (8 % (64 mmol/mol) in patients over
75 years), the overall proportion of patients achieving
the composite control objectives remained low (less than
one out of six), and it remained lower in women as well.
Men had lower BMI values than women, and in all age
groups the proportion of male patients with a BMI less
than 30 kg/m2 was greater than that of females. The largest
difference in BMI was more than 10 percentage points
among the 65–74 year age group. In both men and women,
the prevalence of obesity decreased as age increased
(p <0.001). The prevalence of smoking was lower among
women than among men in all age groups (Table 2).
Discussion
Only a minority of patients with type 2 diabetes met the
composite target objectives for glycemic control, blood
pressure, and lipid control. Patients under 65 years and
women had poorer control of glycaemia and cardiovas-
cular risk factors.
This study had some limitations. First, our analysis
was confined to persons with diagnosed diabetes who
attended the Regional Heath Service; we had no infor-
mation about persons using private medical insurance or
those with undiagnosed diabetes. Second, there was a
risk of information bias from the use of existing elec-
tronic clinical records. We cannot rule out that the
patients with missing data were different from those
with properly recorded data and that they had a different
degree of cardiometabolic control. In the case of BMI
and smoking status the high proportion of missing
values prevents drawing any conclusion about them.
The main strengths of this study were that it used data
from real medical practice and it included patients from
any age, different health status and varying social condi-
tions. Additional strengths may be the large number of
data entries available, and the fact that patients who
attend the Regional Health Service encompass 96 % of
the population in the region. Finally, the sex and age
stratified analysis provided an accurate snapshot to iden-
tify gaps in the quality of care.
The average levels of HbA1c (7.10 %, 54 mmol/mol) in
our population were similar or slightly lower than those
from other Spanish regions [13] and European countries
[19, 20]. The proportion of patients with good glycemic
control (60 %) was higher than the average proportion of
the eight European countries (54 %) reported by Stone,
but it was within the range of the countries that partici-
pated in the study [21]. It was also higher than the pro-
portions found in other Spanish regions several years
ago (56 %), in Canada (53 %), and in the USA (52 %)
[13, 22–24]. There were some meaningful sex- and age-
related differences in glycemic control. Men displayed
better glycemic control than women, which is in line
with some results previously reported [13, 19], and
patients younger than 65 years, particularly males,
appeared to have poorer glycemic control than older
patients. The highest proportion of patients without a
blood test performed in the previous 15 months and the
highest proportion of patients with an HbA1c greater
than 10 % (>86 mmol/mol) was found in the younger
than 65 years age group. Among males, this age group
also had the lowest proportion of patients with an
HbA1c level less than 7 % (53 mmol/mol). Among
women, such a difference was not observed, suggesting
that the relationship between age and the achievement
of control targets may follow a partially different
pattern.
The proportion of patients meeting the blood pressure
target of 130/80 mmHg in our study (40 %) was between
8 and 30 percentage points higher than those found in
other European countries, but it was 10 percentage
points lower than those reported in Canada, and in the
USA from the National Health and Nutrition Examin-
ation Survey (NANHES) [21, 23, 24]. The low degree of
achievement of the 130/80 mmHg target has recurrently
prompted the question of whether it is a realistic target
for medical practice or whether more feasible targets,
such as 140/90 mmHg, should be implemented. How-
ever, the better results reported from other populations
indicate that further improvements in blood pressure
control should be considered feasible in European
populations.
Regarding lipid control, the proportion of patients
who met the 100 mg/dl target for LDL in Navarre
(40.5 %) was similar to those reported from the Spanish
studies conducted in other regions and cited above, with
differences of less than three percentage points. How-
ever, they were 15 percentage points lower than the pro-
portions reported by Stone for eight European countries
and the NHANES (2007–2010) for the USA. Addition-
ally, we found poorer achievement of LDL control tar-
gets among women and younger patients. Beyond its
statistical significance, it was remarkable that the pro-
portion of target-meeting patients was an average of
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approximately 8 percentage points lower among women
than among men and over 10 percentage points lower
among patients younger than 65 years than among those
older than 75 years. In other words, in terms of risk esti-
mates, a woman’s likelihood of achieving cholesterol tar-
gets was notably lower than that of a man.
Only a minority (14 %) of patients met all three con-
trol targets for HbA1c, BP, and LDL. Even if less strin-
gent targets are combined, such as 8 % HbA1c
(64 mmol/mol) for patients over 75 years, the composite
target is only met by less than one-fifth of the patients.
Women and patients under 65 years of age were less
likely than men and older adults to achieve the compos-
ite control targets, following the same patterns observed
for LDL and HbA1c. Because early control of the risk
factors for microvascular and macrovascular disease may
confer benefits, these results suggest that women and
younger patients with diabetes require further attention.
There are few studies about the inequalities in cardio-
metabolic control among patients with diabetes that
combine sex and age. Poorer results among younger
adults were also found by NHANES (2007–2010) in the
USA, in which younger adults were less likely than older
adults to meet goals for treatment and preventive prac-
tices. In general, sex inequalities were more often
reported to be related to cardiovascular risk factors, and
poorer glycemic control results were reported to be
more related to younger ages, irrespective of the pres-
ence of complications [13, 19, 20, 25]. We can only
speculate about possible explanations for the observed age
and sex-related inequalities in the achievement of the con-
trol targets in our population. Because the Regional
Health Service provide universal coverage in the commu-
nity and the same primary care teams provide care to all
age groups, we thought that the poorer results of glycemic
control among younger patients were more likely related
to their personal characteristics, such lifestyle or work ac-
tivity, rather than to access to health care or the quality of
the health care received. Among men older than 65 years,
we observed an increase in the proportion of patients who
met glycemic targets, but this was not observed in women,
which suggests that there may be more significant changes
in lifestyles after retirement in men than in women.
In connection with sex-related control inequalities of
cardiovascular risk factors, physician attentiveness and
selective treatment prescription were suggested as fac-
tors that may account for the observed gaps. However,
studies conducted in Europe did not support this hy-
pothesis because they did not find therapies to be less
stringent among females [22, 25]. More adverse cardio-
vascular profiles among women and biological differ-
ences between men and women have been suggested to
explain the greater diabetes-related cardiovascular risk
ratios observed among women [26, 27]. Our results
support the idea that more adverse cardiovascular pro-
files among women may play a role.
Conclusions
This study provides representative snapshots of the de-
gree of cardiometabolic control in a population of pa-
tients with diabetes in a Spanish region. Only a minority
of patients met the goals of HbA1c, LDL, and blood
pressure. Female patients and younger patients were less
likely to achieve the control goals. The high prevalence
of type 2 diabetes implies that a large portion of the
population could benefit from general improvements in
control and from reducing age and sex inequalities.
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